Navigation Links
Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
Date:12/15/2011

PRINCETON, N.J., Dec. 15, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein. Initial development work will be covered pursuant to a previously issued $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant enabling development of thermo-stable ricin and anthrax vaccines.

The option encompasses an issued U.S. patent that covers engineered variants of protective antigen (PA) developed in the Harvard Medical School laboratory of Dr. John Collier.  PA is the principal determinant of protective immunity to anthrax. Soligenix believes that it will be able to develop the Collier anthrax vaccine with an efficacy profile superior to other anthrax vaccines.

There has been a major effort on the part of the federal government to develop improved vaccines for use both pre- and post anthrax exposure. The vaccine currently in use, known as AVA (anthrax vaccine adsorbed), consists of a defined, but impure, mixture of bacterial components. AVA is FDA approved, but requires multiple injections followed by annual boosters. Vaccines such as AVA or others based on purified, native recombinant PA (rPA) sequences induce antibodies that neutralize anthrax holotoxin and can strongly protect animals from inhaled anthrax spores.  To date, the government has funded more than $4 billion in anthrax vaccine development and commercial contracts.

"We are pleased to secure from Harvard option rights under the patent that covers this promising anthrax vaccine and to initiate its development under our existing grant funding," stated Christopher J. Schaber, PhD, President and CEO of Soligenix. "We b
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Reports Third Quarter 2011 Financial Results
2. Soligenix Announces Formation of Pediatric Crohns Disease Medical Advisory Board
3. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
4. Soligenix Reports Second Quarter 2011 Financial Results and Reviews Accomplishments
5. Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
6. Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
7. Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
8. Soligenix to Present at 13th Annual BIO CEO & Investor Conference
9. Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
10. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  Ameritox SM , the nation,s leader in ... Drugs to Heroin," a research report that provides concrete ... examines deadly trends that have created a unique heroin ... The report is based on data ... It examines five trends that distinguish the heroin abuse ...
(Date:9/2/2014)... , Spanje, September 2, 2014 ... GARFIELD AF Registry bij het ESC CONGRESS ... bij patiënten met risico op beroerte in ... Gegevens van bijna 12.500 patiënten ingeschreven ... FIELD-Atrial Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief ...
(Date:9/2/2014)... 2014 Donald Spector , a renowned ... 8,823,512 for a Wearable Biosensor, which will issue today, ... this field.  Mr. Spector holds some of the earliest ... made today by New York College of Health Professions, ... of world-class intellectual properties.  New York College noted that ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5
... AMN Healthcare Services, Inc. (NYSE: AHS ), the largest ... quarterly conference call to discuss third quarter results on Thursday, ... also expects to issue an earnings news release on Thursday, ... 4:00 p.m. Eastern Time. , A live webcast of the ...
... CPhI Worldwide and connected events - the global pharma ingredients and ... - 15 October for its 20th staging. , The co-located ... technology events are joined for 2009 under the Where Pharma ... The new platform markedly reflects the notable convergence of the pharma ...
Cached Medicine Technology:AMN Healthcare Services to Host 2009 Third Quarter Earnings Conference Call on Thursday, October 29, 2009 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 3
(Date:9/2/2014)... York, NY (PRWEB) September 02, 2014 ... VisitandCare.com , was designed to help doctors manage ... practices to boost patient conversion rates and clink revenue. ... a 60 percent increase in sales revenue and a ... one-of-a-kind CRM software in their own healthcare practices. , ...
(Date:9/2/2014)... California, San Diego School of Medicine have identified an ... The findings, reported in the current issue of PNAS, ... mortality worldwide. An estimated 40,000 women in America will ... American Cancer Society. , "The take-home message of the ... target breast cancer metastasis through a pathway regulated by ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 For the ... IT security and network services company, has been named ... Inc. magazine's Inc. 5000 list highlights America's fastest growing ... year since the list inception in 2007. , Landing ... grown 144 percent over the past three years. , ...
(Date:9/2/2014)... (trade name: Betmiga) has been approved since December 2012 ... an early benefit assessment pursuant to the Act on ... the German Institute for Quality and Efficiency in Health ... added benefit over the appropriate comparator therapy specified by ... advantage with regard to side effects: Dry mouth was ...
(Date:9/2/2014)... A New York City based company is ... yet revolutionary, product that will have far-reaching, ... care costs for Americans. , REMIND-A-CAP™ is ... control in the user's hands. It's a simple device ... date of intake by simply turning a knob. No ...
Breaking Medicine News(10 mins):Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Enzyme controlling metastasis of breast cancer identified 2Health News:CentraComm Named to Inc. 5000 for 8th Consecutive Year 2Health News:Mirabegron for overactive bladder: Added benefit not proven 2Health News:Mirabegron for overactive bladder: Added benefit not proven 3Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2
... first discovered in China nearly 5000 years ago, has ... heart disease, stroke and certain types of cancer. Researchers ... two compounds found in green tea, EGCG (epigallocatchin gallate) ... blocking the enzyme that destroys cartilage. Dr David Buttle, ...
... Venous thromboembolism is a condition which causes clotting in ... five- to 10-day course of heparin followed by three ... the problem with this treatment is that once the ... rates of this problem are reduced if the patient ...
... in the February issue of the British Medical Journal has ... at risk of heart disease later in life than those ... infant in Scotland during the years 1981-85, were identified as ... or repeated miscarriages. Then, during 1981 to 1999, the researchers ...
... a common problem in the knees, is a form ... change. A key problem involved in in these type ... salt called hyaluronan within the fluid that moisturizes the ... injections are being given to humans since 1987, after ...
... in appetite control, called ghrelin, has been identified by ... have demonstrated the effect of the hormone on the ... specialized neurons in the hypothalamus involved in weight regulation. ... the ability to stimulate feeding when introduced to specialized ...
... not all that well understood, but is believed to ... winter months. Winter depression involves suffering from feelings of ... and nights get shorter. Other SAD symptoms include overeating, ... than usual. Researchers have now found that light therapy// ...
Cached Medicine News:Health News:Treatment over a longer period for blood clotting 2Health News:Miscarriage during pregnancy and heart disease linked 2Health News:Scientists locate key hormone involved in appetite control 2
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Cushing-Hopkins periosteal elevator, Gutsch handle, blade width 7/16" (11 mm), length 7 5/8" (194 mm)....
Cushing Little Joker periosteal elevators, solid handle, blade width 1/4" (6 mm), length 7 1/2" (191 mm)....
Lederer periosteal elevators....
Medicine Products: